We could not find any results for:
Make sure your spelling is correct or try broadening your search.
Crinetics Pharmaceuticals Inc is a clinical-stage pharmaceutical company focused on the discovery, development, and commercialization of novel therapeutics for rare endocrine diseases and endocrine-related tumors. Crinetics Pharmaceuticals Inc is a clinical-stage pharmaceutical company focused on the discovery, development, and commercialization of novel therapeutics for rare endocrine diseases and endocrine-related tumors.
SAN DIEGO, Jan. 10, 2025 (GLOBE NEWSWIRE) -- Crinetics Pharmaceuticals, Inc. (Nasdaq: CRNX) today announced that on January 10, 2025, the Compensation Committee of the Board of Directors granted...
Substantial, Rapid and Sustained Statistically Significant Reductions of Key Biomarkers Achieved Across Doses, Including up to 80% Mean Reduction of Androstenedione Meaningful Improvements...
SAN DIEGO, Jan. 06, 2025 (GLOBE NEWSWIRE) -- Crinetics Pharmaceuticals, Inc. (Nasdaq: CRNX) today announced that Scott Struthers, Ph.D., Founder and Chief Executive Officer of Crinetics, will...
SAN DIEGO, Dec. 16, 2024 (GLOBE NEWSWIRE) -- Crinetics Pharmaceuticals, Inc. (Nasdaq: CRNX) today announced the appointment of Isabel Kalofonos as Chief Commercial Officer. Ms. Kalofonos will...
SAN DIEGO, Dec. 10, 2024 (GLOBE NEWSWIRE) -- Crinetics Pharmaceuticals, Inc. (Nasdaq: CRNX) today announced that on December 10, 2024, the Compensation Committee of the Board of Directors...
Period | Change | Change % | Open | High | Low | Avg. Daily Vol | VWAP | |
---|---|---|---|---|---|---|---|---|
1 | -10.85 | -20.9297839506 | 51.84 | 53.55 | 40.56 | 632808 | 50.18547768 | CS |
4 | -14.48 | -26.1042004687 | 55.47 | 56.265 | 40.56 | 731059 | 52.61235448 | CS |
12 | -17.92 | -30.419283653 | 58.91 | 62.53 | 40.56 | 650171 | 55.93393821 | CS |
26 | -7.47 | -15.4147750722 | 48.46 | 62.53 | 40.56 | 679010 | 54.02804824 | CS |
52 | 3.34 | 8.87118193891 | 37.65 | 62.53 | 35.24 | 764586 | 48.52274872 | CS |
156 | 15.45 | 60.4933437745 | 25.54 | 62.53 | 15.23 | 620501 | 34.0356781 | CS |
260 | 14.48 | 54.6208977744 | 26.51 | 62.53 | 10.63 | 439605 | 31.6361068 | CS |
It looks like you are not logged in. Click the button below to log in and keep track of your recent history.
Support: +44 (0) 203 8794 460 | support@advfn.com
By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions